Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

ABSTRACT: The investigators hypothesize that intermittent first-line Panitumumab plus FOLFIRI is effective as the same regimen given continuously, in unresectable metastatic RAS and BRAF wild type colorectal cancer patients. Correlative studies on tumor and blood samples could identify potential biomarkers of efficacy and help defining personalized treatment strategy.

DISEASE(S): Colorectal Cancer Stage Iv,Colorectal Neoplasms

PROVIDER: 2342062 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR